Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-II: Trospium vs Oxybutynin CSF levels and memory
NCT01178827Phase 4Completed
- Sponsor
- Allergan
- Start
- Aug 2010
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of trospium in overactive bladder (OAB) (3 arms), sponsored by Allergan. Primary endpoints: Cerebral Spinal Fluid Levels of Sanctura XR at Day 10 and Cerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2. Started Aug 2010; status: completed.
02
Drugs
trospium
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01178827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01178827.